Bharat Biotech`s Covaxin shows 77.8 % efficacy against COVID: Lancet study

“COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2 per cent,” the official statement issued by Bharat Biotech said citing the study by the Lancet.